EP3307805B1 - Curable compositions containing benzoxazine epoxy blend and use thereof - Google Patents
Curable compositions containing benzoxazine epoxy blend and use thereof Download PDFInfo
- Publication number
- EP3307805B1 EP3307805B1 EP16728796.0A EP16728796A EP3307805B1 EP 3307805 B1 EP3307805 B1 EP 3307805B1 EP 16728796 A EP16728796 A EP 16728796A EP 3307805 B1 EP3307805 B1 EP 3307805B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- fibers
- resin composition
- benzoxazine
- curable
- curable resin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LVGAZNUUPCRHIJ-UHFFFAOYSA-N C(c(cc1)cc(C2)c1OCN2c1ccccc1)c(cc1)cc(C2)c1OCN2c1ccccc1 Chemical compound C(c(cc1)cc(C2)c1OCN2c1ccccc1)c(cc1)cc(C2)c1OCN2c1ccccc1 LVGAZNUUPCRHIJ-UHFFFAOYSA-N 0.000 description 1
- JZYYZPITDRKMHZ-UHFFFAOYSA-N CC(c(cc1C2)ccc1OCN2c1ccc(C)cc1)(c(cc1C2)ccc1OCN2c1ccc(C)cc1)c(cc1)cc(C2)c1OCN2c1ccc(C)cc1 Chemical compound CC(c(cc1C2)ccc1OCN2c1ccc(C)cc1)(c(cc1C2)ccc1OCN2c1ccc(C)cc1)c(cc1)cc(C2)c1OCN2c1ccc(C)cc1 JZYYZPITDRKMHZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/38—Layered products comprising a layer of synthetic resin comprising epoxy resins
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
- C08L79/02—Polyamines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G59/00—Polycondensates containing more than one epoxy group per molecule; Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups
- C08G59/18—Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups ; e.g. general methods of curing
- C08G59/20—Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups ; e.g. general methods of curing characterised by the epoxy compounds used
- C08G59/22—Di-epoxy compounds
- C08G59/24—Di-epoxy compounds carbocyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
- C08J5/04—Reinforcing macromolecular compounds with loose or coherent fibrous material
- C08J5/0405—Reinforcing macromolecular compounds with loose or coherent fibrous material with inorganic fibres
- C08J5/042—Reinforcing macromolecular compounds with loose or coherent fibrous material with inorganic fibres with carbon fibres
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
- C08J5/04—Reinforcing macromolecular compounds with loose or coherent fibrous material
- C08J5/0405—Reinforcing macromolecular compounds with loose or coherent fibrous material with inorganic fibres
- C08J5/043—Reinforcing macromolecular compounds with loose or coherent fibrous material with inorganic fibres with glass fibres
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
- C08J5/04—Reinforcing macromolecular compounds with loose or coherent fibrous material
- C08J5/046—Reinforcing macromolecular compounds with loose or coherent fibrous material with synthetic macromolecular fibrous material
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
- C08J5/24—Impregnating materials with prepolymers which can be polymerised in situ, e.g. manufacture of prepregs
- C08J5/241—Impregnating materials with prepolymers which can be polymerised in situ, e.g. manufacture of prepregs using inorganic fibres
- C08J5/243—Impregnating materials with prepolymers which can be polymerised in situ, e.g. manufacture of prepregs using inorganic fibres using carbon fibres
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/16—Nitrogen-containing compounds
- C08K5/34—Heterocyclic compounds having nitrogen in the ring
- C08K5/35—Heterocyclic compounds having nitrogen in the ring having also oxygen in the ring
- C08K5/357—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L63/00—Compositions of epoxy resins; Compositions of derivatives of epoxy resins
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2363/00—Characterised by the use of epoxy resins; Derivatives of epoxy resins
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2379/00—Characterised by the use of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen, or carbon only, not provided for in groups C08J2361/00 - C08J2377/00
- C08J2379/02—Polyamines
Definitions
- PMC polymer matrix composite
- reinforcement fibers such as carbon, glass and aramid fibers
- matrix resins used in PMC materials thermosetting resins are mainly used because of their high solvent resistance and thermal resistance.
- thermosets which belong to a class of resins that crosslink and form a three-dimensional network structure when cured. Once cured, the network structure is irreversible and cannot be reshaped or made to flow below its decomposition temperature.
- Epoxy resins are often used as polymeric matrix material because of the adhesiveness between the epoxy resins and the reinforcing fibers, and the mechanical properties such as strength and stiffness of the composite material obtained.
- Many aerospace applications use amine-cured, multifunctional epoxies that require curing at elevated temperatures and pressures. Toughened epoxy containing thermoplastics and/or reactive rubber compounds to counteract brittleness due to high degree of crosslinking have become the norm in composite airframes.
- Benzoxazines offers a number of advantages as compared to other thermoset resins such as epoxies. Those advantages include relatively long shelf-life, molecular design flexibility, low cost, high glass transition temperature (T g ), high modulus, relatively low viscosities, good flame retardant properties, low moisture absorption, no by-products released during curing and very low shrinkage upon curing. Furthermore, benzoxazines are capable of being self-cured upon heating; i.e. there is no need for an additional curing agent. However, currently available multifunctional benzoxazines are glassy solids at temperatures below 120°C making them difficult to process using standard aerospace techniques such as prepregging and resin infusion.
- WO 2016/109406 describes a meta-substituted trifunctional benzoxazine monomer, a reaction product composition containing the meta-substituted trifunctional benzoxazine monomer as a major component, and use thereof in curable resin compositions and composite materials.
- hot-wet compressive performance i.e., hot-wet open hole compression or HW-OHC strength under hot/wet conditions
- HW-OHC strength under hot/wet conditions hot-wet open hole compression
- the OHC strength of many existing PMC materials is typically constant at room temperature (e.g. 21° C) or below but can deteriorate significantly at elevated temperatures when saturated with moisture. A high temperature together with moisture has been known to reduce the composite compressive strengths.
- a curable resin composition capable of providing good OHC performance at elevated temperatures, e.g. >105°C, when used in polymer matrix composites.
- This resin composition includes, as major components, one or more multifunctional benzoxazine compounds and cycloaliphatic epoxy resin.
- One aspect of the present disclosure is directed to a curable benzoxazine-epoxy hybrid resin composition capable of providing good OHC performance at elevated temperatures, e.g. >105°C, more specifically, 121 - 149°C (or 250-350 °F), when used in polymer matrix composites.
- this resin composition includes, as major components:
- curable composition refers to a composition prior to curing and a "cured matrix resin” refers to a cured resin produced from curing the curable composition.
- the weight ratio of (A) epoxy resin component to (B) tri-functional benzoxazine component may be 5:95 to 90:10, and in some embodiments, 20:80 to 70:30.
- the combination of components (A) and (B) constitutes for more than 50% by weight of the composition. In another embodiment, the combination of components (A) and (B) constitutes for more than 80% by weight of the composition.
- the cycloaliphatic epoxy resin is used as the epoxy component because it provides a good balance of fracture toughness, glass transition temperature (T g ) and process-abilitly as compared to other types of epoxy resins.
- Suitable cycloaliphatic epoxies are compounds that contain at least one cycloaliphatic ring and at least two oxirane rings per molecule.
- the cycloaliphatic epoxy is 3',4'- epoxycyclohexyl-3,4-epoxycyclohexane carboxylate, represented by the following structure:
- This epoxy of structure is commercially available as Araldite® CY-179 from Huntsman Advanced Materials.
- Other examples of cycloaliphatic epoxies include: EPONEX epoxy resins, e.g. EPONEX Resin 1510, from Momentive Specialty Chemicals; Epotec® epoxy resins, e.g. YDH 184, YDH 3000, from Aditya Birla Chemicals; ERLTM 4221 (3,4-epoxycyclohexylmethyl-3',4'-epoxycyclohexane carboxylate) from Dow Chemical.
- the tri-functional benzoxazine compound suitable for the purposes herein include the following compounds:
- the tri-functional benzoxazines disclosed herein may be synthesized by reacting tris-phenols with aromatic amines and formaldehyde using conventional solvent-based or solventless synthesis methods. More specifically, the aniline tris benzoxazine (C) may be synthesized by reacting 1,1,1-tris(4-hydroxyphenyl)ethane with aniline and para formaldehyde (or p-formaldehyde). The p-tris benzoxazine (2) may be synthesized by reacting 1,1,1-tris(4-hydroxyphenyl)ethane with p-formaldehyde and p-toluidine.
- aniline tris benzoxazine (C) may be synthesized by reacting 1,1,1-tris(4-hydroxyphenyl)ethane with aniline and para formaldehyde (or p-formaldehyde).
- the p-tris benzoxazine (2) may be synthesized by react
- the phenol compound is highly effective as a catalyst (or cure accelerator) for the benzoxazine-epoxy resin system of the present disclosure.
- An example of a suitable phenol compound is thiodiphenol (TDP) represented by the following structure:
- phenol compounds examples include 4,4'-Ethylidenebisphenol, 4,4'-[1-[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenyl]ethylidene]bisphenol, 4-sec-buytl-2,6,-ditert-butylphenol, 4,4'-(9-fluoroenylidene)-diphenol, 4,4'-(1-3-phenylenediisopropylidene)bisphenol, 4,4' cyclohexylidenebisphenol, 4,4'-isopropylidenebis2,6-dimethylphenol. If present, the amount of phenol compound may be up to 15% by weight based on the total weight of the composition.
- the curable resin composition further includes (D) a di-functional benzoxazine compound.
- the benzoxazine component in the composition - compounds (B) and (D) - makes up more than 50% by weight based on the total weight of components (A)-(D) or total weight of the composition when there are other additives.
- the di-functional benzoxazine compound is characterized by having two oxazine rings.
- Suitable di-functional benzoxazines may be represented by the following generic formula I: where
- the arylene group is phenylene.
- the groups attached to the phenylene group may be configured in para- or meta-positions relative to each other.
- the aryl group is phenyl.
- the group Z 1 may be linear or non-linear, and is typically linear.
- the group Z 1 is preferably bound to the benzyl group of each of the benzoxazine moieties at the para-position relative to the oxygen atom of the benzoxazine moieties, as shown in formula (I), and this is the preferred isomeric configuration.
- the group Z 1 may also be attached at either of the meta-positions or the ortho-position, in one or both of the benzyl group(s) in the bis-benzoxazine compound.
- the group Z 1 may be attached to the benzyl rings in a para/para; para/meta; para/ortho, meta/meta or ortho/meta configuration.
- the difunctional benzoxazine resin component comprises a mixture of isomers, preferably wherein the major portion of the mixture is the para/para isomer shown in structure IV, and preferably this is present in at least 75 mol%, preferably at least 90 mol%, and preferably at least 99 mol%, of the total isomeric mixture.
- the difunctional benzoxazine is selected from compounds wherein Z 1 is selected from -C(CH 3 ) 2 -, -CH 2 - and 3,3-isobenzofuran-1(3 H )-one, i.e. benzoxazine derivatives of bisphenol A, bisphenol F and phenolphthalein.
- the difunctional benzoxazine is selected from compounds wherein R 1 and R 2 are independently selected from aryl, preferably phenyl.
- the aryl group may be substituted, preferably wherein the substituent(s) are selected from C 1-8 alkyl, and preferably wherein there is a single substituent present on at least one aryl group.
- C 1-8 alkyl includes linear and branched alkyl chains.
- R 1 and R 2 are independently selected from unsubstituted aryl, preferably unsubstituted phenyl.
- Suitable di-functional benzoxazines include:
- di-functional benzoxazines disclosed herein may be synthesized by reacting polyhydric phenols, specifically, bisphenols or, with aromatic amines and formaldehyde.
- Some di-functional benzoxazines such as Bisphenol-A and Bisphenol F benzoxazines are commercially available.
- Toughening agents may be added to produce a toughened matrix resin suitable for high-strength composites, such as those used in aerospace application.
- Suitable toughening agents include, but are not limited to, thermoplastic toughening agents such as polyethersulphone (PES), co-polymer of PES and polyetherethersulphone (PEES), elastomers, including liquid rubbers having reactive groups, particulate toughening agents such as thermoplastic particles, glass beads, rubber particles, and core-shell rubber particles.
- Functional additives may also be included in the curable composition to influence one or more of mechanical, rheological, electrical, optical, chemical, flame resistance and/or thermal properties of the cured or uncured resin composition.
- functional additives include, but are not limited to, fillers, color pigments, rheology control agents, tackifiers, conductive additives, flame retardants, ultraviolet (UV) protectors, and the like.
- UV ultraviolet
- additives may take the form of various geometries including, but are not limited to, particles, flakes, rods, and the like.
- the total amount of optional additives, including toughener(s) and functional additive(s) is up to 15% by weight based on the total weight of the composition.
- the curable composition as discussed above may be combined with reinforcement fibers to form a composite material.
- Reinforcing fibers may take the form of short fibers, continuous fibers, filaments, tows, bundles, sheets, plies, and combinations thereof.
- Continuous fibers may further adopt any of unidirectional, multidirectional, non-woven, woven, knitted, stitched, wound, and braided configurations, as well as swirl mat, felt mat, and chopped-fiber mat structures.
- the composition of the fibers may be varied to achieve the required properties for the final composite structure.
- Exemplary fiber materials may include, but are not limited to, glass, carbon, aramid, quartz, polyethylene, polyester, poly-p-phenylene-benzobisoxazole (PBO), boron, polyamide, graphite, silicon carbide, silicon nitride, and combinations thereof.
- PBO poly-p-phenylene-benzobisoxazole
- the reinforcing fibers have a tensile strength of greater than 3500 MPa.
- Reinforcement fibers may be present in the composite material at a content of 60% to 75%, preferably at least 68%, by weight.
- continuous fibre made of, for example, glass, aramid (e.g. Kevlar) or carbon, at 30% to 70%, more especially 50% to 70% by volume.
- the reinforcing fibers may be impregnated or infused with the curable composition using conventional processing techniques such as, but not limited to prepregging and resin infusion.
- the term "impregnate” refers to the introduction of a curable matrix resin material to reinforcement fibers so as to partially or fully encapsulate the fibers with the resin.
- the matrix resin for making prepregs may take the form of resin films or liquids. Moreover, the matrix resin is in a curable or uncured state prior to impregnation. Impregnation may be facilitated by the application heat and/or pressure.
- the impregnating method for making prepregs may include:
- the prepregs After impregnation, the prepregs are in a curable/partially cured state and are still pliable. Prepregs are laid up onto each other in a particular orientation on a tool to form a laminate. The prepreg lay-up is then subjected to curing to form a composite part. Pressure may be applied during curing, dependent on the structural part and configuration, but the use of an autoclave is most common for high-performance structural parts.
- Curing may be carried out at elevated temperature > 175°C, preferably in the range of 180 - 200 °C.
- a desirable cure profile may be ramp from 25°C to 180°C at 2°C/min. and hold at 180°C for 2 hours then continue to ramp up to 200°C and hold for 2 additional hours then cool down to RT.
- curing is carried out with the application of elevated pressure to restrain deforming effects of escaping gases, or to restrain void formation, e.g. at pressure of 6.8 - 8.2 bars.
- composite parts may be formed using a resin infusion process, which covers processing techniques such as Resin Transfer Molding (RTM) and Vacuum Assisted Resin Transfer Molding (VARTM).
- RTM Resin Transfer Molding
- VARTM Vacuum Assisted Resin Transfer Molding
- the first step is to form a dry fiber preform in the shape of the desired structural part.
- the preform generally includes a number of fabric layers or plies made from dry reinforcement fibers that impart the desired reinforcing properties to a resulting composite part.
- the preform is placed in a mold.
- the curable resin composition is injected directly into fiber preform, and then the resin-infused preform is cured.
- a catalyst e.g. the phenol compound disclosed herein, is included.
- RD2011-29 (Bisphenol A benzoxazine) and Araldite CY179 (cycloaliphatic epoxy) were supplied by Huntsman Advanced Materials.
- TDP refers to thiodiphenol.
- Pa-Type BOX was a monofunctional benzoxazine supplied by Shikoku Chemical Corporation and is represented by the following structure:
- Tris BOX refers to the aniline tris benzoxazine compound (1) described above and was synthesized according the following reaction:
- the oil bath was then heated to 130°C, when the internal temperature was above 110°C the reaction timer was set for 30 minutes. After 30 minutes, the molten reaction mixture was poured into an aluminum dish using a spatula to distribute the resin evenly over the pan and allowed to cool to room temperature. The resulting gold crystalline product was then ground into a powder. The powder was washed twice in 2L of a 1N NaOH solution at 70°C and in 2L of water at the same temperature as many times as needed to obtain a neutral pH. The product was dried in a vacuum oven for a week at 45°C.
- p-Tris-BOX refers to the p-tris benzoxazine compound (2) discussed above and was synthesized according to the method disclosed in U.S. Patent Application No. 14/562,799 , filed on 12/08/2014 and assigned to Cytec Industries Inc.
- Resin films were formed from the resin formulations disclosed on Table 1. Each resin film had a film weight of -39 gsm. Prepregs were made by impregnating unidirectional IM7 carbon fibers in web form with the resin films using a hot-melt lamination method. The target fabric areal weight (FAW) for the carbon fibers was 145 gsm and 35% resin content per prepreg. With the use of hot- melt prepregging equipment, two resin films were applied to a unidirectional carbon fiber web on both the top and bottom simultaneously, and impregnation was done with the aid of a hot plate heated to temperature between 160°F and 230°F.
- FAW target fabric areal weight
- Composite laminate was made by laying up 24 prepreg plies according to orientation [+45/90/-45/0]3s to create a composite panel. During composite panel fabrication, debulking was also carried out every 4 th ply, for 3 minutes under vacuum. Subsequently, the composite panel was vacuum bagged and cured in an autoclave at 8.16 bars for 2h at 180°C and then an additional 2h at 200°C.
- the cured composite panels were tested to determine open hole compression (OHC) and open hole tension (OHT) performance using ASTM test methods D6484 and D766 respectively.
- test specimens of cured composite panels were made. A 0.635cm, 0.25 inch hole was drilled in the center of each test specimen. Specimens were conditioned by immersing specimens in a water bath set at 71 °C for 2 weeks.
- T g was measured by Dynamic Mechanical Thermal Analysis (DMTA). It was observed that the tri-functional benzoxazines lowered the T g of the benzoxazine composites that contained no cycloaliphatic epoxy (Formulation 9). Again, the increase in T g was achieved with having both the cycloaliphatic epoxy and tri-functional benzoxazines in the resin system.
- DMTA Dynamic Mechanical Thermal Analysis
- Composite panels based on Formulations 5, 9 had tension values greater than the composite panel based on Formulation 1. More importantly, the combination of tri-functional benzoxazine and epoxy (Formulation 5) did not cause a decrease in the OHT strength, instead an increase was obtained. This is unexpected because an increase in compressive strength is typically accompanied by a loss in tensile strength. This was not the case with the use of Formulation 5.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Manufacturing & Machinery (AREA)
- Inorganic Chemistry (AREA)
- Reinforced Plastic Materials (AREA)
- Epoxy Resins (AREA)
- Phenolic Resins Or Amino Resins (AREA)
Description
- The present application claims the benefit of prior
.U.S. Provisional Application No. 62/174,759 filed on June 12, 2015 - In recent years, polymer matrix composite (PMC) materials have been used in high-performance structures such as airplane parts and automobile parts as high-strength, low weight materials to replace metals. PMC materials contain reinforcement fibers, such as carbon, glass and aramid fibers, embedded in a polymeric matrix material. As the matrix resins used in PMC materials, thermosetting resins are mainly used because of their high solvent resistance and thermal resistance.
- The polymers most widely used in PMC are thermosets, which belong to a class of resins that crosslink and form a three-dimensional network structure when cured. Once cured, the network structure is irreversible and cannot be reshaped or made to flow below its decomposition temperature.
- Epoxy resins are often used as polymeric matrix material because of the adhesiveness between the epoxy resins and the reinforcing fibers, and the mechanical properties such as strength and stiffness of the composite material obtained. Many aerospace applications use amine-cured, multifunctional epoxies that require curing at elevated temperatures and pressures. Toughened epoxy containing thermoplastics and/or reactive rubber compounds to counteract brittleness due to high degree of crosslinking have become the norm in composite airframes.
- Benzoxazines offers a number of advantages as compared to other thermoset resins such as epoxies. Those advantages include relatively long shelf-life, molecular design flexibility, low cost, high glass transition temperature (Tg), high modulus, relatively low viscosities, good flame retardant properties, low moisture absorption, no by-products released during curing and very low shrinkage upon curing. Furthermore, benzoxazines are capable of being self-cured upon heating; i.e. there is no need for an additional curing agent. However, currently available multifunctional benzoxazines are glassy solids at temperatures below 120°C making them difficult to process using standard aerospace techniques such as prepregging and resin infusion.
WO 2016/109406 describes a meta-substituted trifunctional benzoxazine monomer, a reaction product composition containing the meta-substituted trifunctional benzoxazine monomer as a major component, and use thereof in curable resin compositions and composite materials. - The design of composite materials for use in aerospace structures typically takes into account the hot/wet performance of the material. Aircrafts must consider the extreme environmental factors such as high temperatures and high level of humidity since they can experience high temperatures for hours while the humidity levels are unknown.
- One of the important properties of aerospace composite materials is the hot-wet compressive performance (i.e., hot-wet open hole compression or HW-OHC strength under hot/wet conditions), by which is meant the way in which the OHC strength decreases at elevated temperatures after a prolonged exposure to moisture.
- It is standard practice to use bolts, rivets and other fasteners to assemble composite laminate for primary structures such as the fuselage of an airplane. The holes that have been drilled to accommodate these fasteners are considered artificial defects and can be the points of failure under compressive stress. OHC testing is the accepted method to predict this failure in composite materials.
- The OHC strength of many existing PMC materials is typically constant at room temperature (e.g. 21° C) or below but can deteriorate significantly at elevated temperatures when saturated with moisture. A high temperature together with moisture has been known to reduce the composite compressive strengths.
- Commercially available resin systems such as Cycom® 977-3 (highly cross-linked epoxy) and Cycom® 5250-4 (bismaleimide) from Cytec Industries Inc. have been developed for high-performance aerospace applications. Composites based on these resin systems exhibit good hot-wet open hole compression (HW-OHC strength) under hot/wet conditions at elevated temperatures, thus they are particularly suitable for making primary structures of airplanes.
- Even though there are numerous publications regarding benzoxazine compounds and synthesis thereof, little is known of their OHC performance under hot-wet conditions at use temperatures normally used for BMI's (i.e 149°C). Benzoxazine-based composites have been considered to have inherently good compressive and tensile strength as compared to that of highly cross-linked epoxy systems and bismaleimide systems. Thus, it would be desirable to have a benzoxazine-containing resin system that can be used for manufacturing high-performance composites with good HW-OHC strength at elevated temperatures, e.g. >105°C. To that end, it is desirable that HW-OHC strength at elevated temperatures is equivalent to or better than that associated with the epoxy and bismaleimide systems for aerospace applications.
- Disclosed herein is a curable resin composition capable of providing good OHC performance at elevated temperatures, e.g. >105°C, when used in polymer matrix composites. This resin composition includes, as major components, one or more multifunctional benzoxazine compounds and cycloaliphatic epoxy resin.
- One aspect of the present disclosure is directed to a curable benzoxazine-epoxy hybrid resin composition capable of providing good OHC performance at elevated temperatures, e.g. >105°C, more specifically, 121 - 149°C (or 250-350 °F), when used in polymer matrix composites. According to one embodiment, this resin composition includes, as major components:
- (A) a cycloaliphatic epoxy resin containing two or more epoxide groups;
- (B) a tri-functional benzoxazine compound according to claim 1; and
- (C) optionally, a phenol compound as a catalyst.
- As used herein, a "curable" composition refers to a composition prior to curing and a "cured matrix resin" refers to a cured resin produced from curing the curable composition.
- The weight ratio of (A) epoxy resin component to (B) tri-functional benzoxazine component may be 5:95 to 90:10, and in some embodiments, 20:80 to 70:30. In one embodiment, the combination of components (A) and (B) constitutes for more than 50% by weight of the composition. In another embodiment, the combination of components (A) and (B) constitutes for more than 80% by weight of the composition.
- The cycloaliphatic epoxy resin is used as the epoxy component because it provides a good balance of fracture toughness, glass transition temperature (Tg) and process-abilitly as compared to other types of epoxy resins. Suitable cycloaliphatic epoxies are compounds that contain at least one cycloaliphatic ring and at least two oxirane rings per molecule. In a preferred embodiment, the cycloaliphatic epoxy is 3',4'- epoxycyclohexyl-3,4-epoxycyclohexane carboxylate, represented by the following structure:
- This epoxy of structure is commercially available as Araldite® CY-179 from Huntsman Advanced Materials. Other examples of cycloaliphatic epoxies include: EPONEX epoxy resins, e.g. EPONEX Resin 1510, from Momentive Specialty Chemicals; Epotec® epoxy resins, e.g. YDH 184, YDH 3000, from Aditya Birla Chemicals; ERL™ 4221 (3,4-epoxycyclohexylmethyl-3',4'-epoxycyclohexane carboxylate) from Dow Chemical.
-
- The tri-functional benzoxazines disclosed herein may be synthesized by reacting tris-phenols with aromatic amines and formaldehyde using conventional solvent-based or solventless synthesis methods. More specifically, the aniline tris benzoxazine (C) may be synthesized by reacting 1,1,1-tris(4-hydroxyphenyl)ethane with aniline and paraformaldehyde (or p-formaldehyde). The p-tris benzoxazine (2) may be synthesized by reacting 1,1,1-tris(4-hydroxyphenyl)ethane with p-formaldehyde and p-toluidine.
-
- Examples of other possible phenol compounds include 4,4'-Ethylidenebisphenol, 4,4'-[1-[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenyl]ethylidene]bisphenol, 4-sec-buytl-2,6,-ditert-butylphenol, 4,4'-(9-fluoroenylidene)-diphenol, 4,4'-(1-3-phenylenediisopropylidene)bisphenol, 4,4' cyclohexylidenebisphenol, 4,4'-isopropylidenebis2,6-dimethylphenol. If present, the amount of phenol compound may be up to 15% by weight based on the total weight of the composition.
- According to another embodiment of the present disclosure, the curable resin composition further includes (D) a di-functional benzoxazine compound.
- In this embodiment, the benzoxazine component in the composition - compounds (B) and (D) - makes up more than 50% by weight based on the total weight of components (A)-(D) or total weight of the composition when there are other additives.
-
- Z1 is selected from a direct bond, -C(R3)(R4)-, -C(R3)(aryl)-, -C(O)-, -S-, -O-, -S(O)-, -S(O)2-, a divalent heterocycle and -[C(R3)(R4)]x-arylene-[C(R5)(R6)]y-, or the two benzyl rings of the benzoxazine moieties may be fused; and
- R1 and R2 are independently selected from alkyl (preferably C1-8 alkyl), cycloalkyl (preferably C5-7 cycloalkyl, preferably C6 cycloalkyl) and aryl, wherein the cycloalkyl and aryl groups are optionally substituted, for instance by C1-8 alkyl, halogen and amine groups, and preferably by C1-8 alkyl, and where substituted, one or more substituent groups (preferably one substituent group) may be present on each cycloalkyl and aryl group;
- in one embodiment, Z1 is selected from a direct bond, -C(R3)(R4)-, -C(R3)(aryl)-, -C(O)-, -S-,-O-, a divalent heterocycle and -[C(R3)(R4)]x-arylene-[C(R5)(R6)]y-, or the two benzyl rings of the benzoxazine moieties may be fused;
- R3, R4, R5 and R6 are independently selected from H, C1-8 alkyl (preferably C1-4 alkyl, and preferably methyl), and halogenated alkyl (wherein the halogen is typically chlorine or fluorine (preferably fluorine) and wherein the halogenated alkyl is preferably CF3); and x and y are independently 0 or 1;
- where Z1 is selected from a divalent heterocycle, it is preferably 3, 3-isobenzofuran-1(3h)-one, i.e. wherein the compound of formula (III) is derived from phenolphthalein;
- where Z1 is selected from -[C(R3)(R4)]x-arylene-[C(R5)(R6)]y-, then the chain linking the two benzoxazine groups may further comprise one or more arylene group(s) and/or one or more -C(R7)(R8)- group(s) where R7 and R8 are independently selected from the groups defined hereinabove for R3.
- In a preferred embodiment, the arylene group is phenylene. In one embodiment, the groups attached to the phenylene group may be configured in para- or meta-positions relative to each other. In a preferred embodiment, the aryl group is phenyl.
- The group Z1 may be linear or non-linear, and is typically linear. The group Z1 is preferably bound to the benzyl group of each of the benzoxazine moieties at the para-position relative to the oxygen atom of the benzoxazine moieties, as shown in formula (I), and this is the preferred isomeric configuration. However, the group Z1 may also be attached at either of the meta-positions or the ortho-position, in one or both of the benzyl group(s) in the bis-benzoxazine compound. Thus, the group Z1 may be attached to the benzyl rings in a para/para; para/meta; para/ortho, meta/meta or ortho/meta configuration. In one embodiment, the difunctional benzoxazine resin component comprises a mixture of isomers, preferably wherein the major portion of the mixture is the para/para isomer shown in structure IV, and preferably this is present in at least 75 mol%, preferably at least 90 mol%, and preferably at least 99 mol%, of the total isomeric mixture.
- In a preferred embodiment, the difunctional benzoxazine is selected from compounds wherein Z1 is selected from -C(CH3)2-, -CH2- and 3,3-isobenzofuran-1(3H)-one, i.e. benzoxazine derivatives of bisphenol A, bisphenol F and phenolphthalein.
- In another embodiment, the difunctional benzoxazine is selected from compounds wherein R1 and R2 are independently selected from aryl, preferably phenyl. In one embodiment, the aryl group may be substituted, preferably wherein the substituent(s) are selected from C1-8 alkyl, and preferably wherein there is a single substituent present on at least one aryl group. C1-8 alkyl includes linear and branched alkyl chains. Preferably, R1 and R2 are independently selected from unsubstituted aryl, preferably unsubstituted phenyl.
-
- The di-functional benzoxazines disclosed herein may be synthesized by reacting polyhydric phenols, specifically, bisphenols or, with aromatic amines and formaldehyde. Some di-functional benzoxazines such as Bisphenol-A and Bisphenol F benzoxazines are commercially available.
- Toughening agents (or tougheners) may be added to produce a toughened matrix resin suitable for high-strength composites, such as those used in aerospace application. Suitable toughening agents include, but are not limited to, thermoplastic toughening agents such as polyethersulphone (PES), co-polymer of PES and polyetherethersulphone (PEES), elastomers, including liquid rubbers having reactive groups, particulate toughening agents such as thermoplastic particles, glass beads, rubber particles, and core-shell rubber particles.
- Functional additives may also be included in the curable composition to influence one or more of mechanical, rheological, electrical, optical, chemical, flame resistance and/or thermal properties of the cured or uncured resin composition. Examples of such functional additives include, but are not limited to, fillers, color pigments, rheology control agents, tackifiers, conductive additives, flame retardants, ultraviolet (UV) protectors, and the like. These additives may take the form of various geometries including, but are not limited to, particles, flakes, rods, and the like.
- If present, the total amount of optional additives, including toughener(s) and functional additive(s) is up to 15% by weight based on the total weight of the composition.
- Another aspect of the present disclosure is directed to composite materials and methods for making the same. The curable composition as discussed above may be combined with reinforcement fibers to form a composite material. Reinforcing fibers may take the form of short fibers, continuous fibers, filaments, tows, bundles, sheets, plies, and combinations thereof. Continuous fibers may further adopt any of unidirectional, multidirectional, non-woven, woven, knitted, stitched, wound, and braided configurations, as well as swirl mat, felt mat, and chopped-fiber mat structures. The composition of the fibers may be varied to achieve the required properties for the final composite structure. Exemplary fiber materials may include, but are not limited to, glass, carbon, aramid, quartz, polyethylene, polyester, poly-p-phenylene-benzobisoxazole (PBO), boron, polyamide, graphite, silicon carbide, silicon nitride, and combinations thereof. For the fabrication of high-strength composite materials, such as those for aerospace and automotive applications, it is preferred that the reinforcing fibers have a tensile strength of greater than 3500 MPa.
- Reinforcement fibers may be present in the composite material at a content of 60% to 75%, preferably at least 68%, by weight. For high-performance structures such as those for industrial and aerospace applications, it is preferred to use continuous fibre made of, for example, glass, aramid (e.g. Kevlar) or carbon, at 30% to 70%, more especially 50% to 70% by volume.
- To form composite materials, the reinforcing fibers may be impregnated or infused with the curable composition using conventional processing techniques such as, but not limited to prepregging and resin infusion.
- The term "impregnate" refers to the introduction of a curable matrix resin material to reinforcement fibers so as to partially or fully encapsulate the fibers with the resin. The matrix resin for making prepregs may take the form of resin films or liquids. Moreover, the matrix resin is in a curable or uncured state prior to impregnation. Impregnation may be facilitated by the application heat and/or pressure.
- As an example, the impregnating method for making prepregs may include:
- (1) Continuously moving fibers through a (heated) bath of molten impregnating matrix resin composition to fully or substantially fully wet out the fibers; or
- (2) Pressing top and bottom resin films against a sheet of continuous unidirectional fibers running in parallel or a fabric web while applying heat at a temperature that cause the resin film to be in a molten state.
- After impregnation, the prepregs are in a curable/partially cured state and are still pliable. Prepregs are laid up onto each other in a particular orientation on a tool to form a laminate. The prepreg lay-up is then subjected to curing to form a composite part. Pressure may be applied during curing, dependent on the structural part and configuration, but the use of an autoclave is most common for high-performance structural parts.
- Curing may be carried out at elevated temperature > 175°C, preferably in the range of 180 - 200 °C. For example a desirable cure profile may be ramp from 25°C to 180°C at 2°C/min. and hold at 180°C for 2 hours then continue to ramp up to 200°C and hold for 2 additional hours then cool down to RT. Preferably, curing is carried out with the application of elevated pressure to restrain deforming effects of escaping gases, or to restrain void formation, e.g. at pressure of 6.8 - 8.2 bars.
- Alternatively, composite parts may be formed using a resin infusion process, which covers processing techniques such as Resin Transfer Molding (RTM) and Vacuum Assisted Resin Transfer Molding (VARTM). To fabricate a composite part through resin infusion, e.g. RTM or VaRTM processes, the first step is to form a dry fiber preform in the shape of the desired structural part. The preform generally includes a number of fabric layers or plies made from dry reinforcement fibers that impart the desired reinforcing properties to a resulting composite part. After the fiber preform has been formed, the preform is placed in a mold. The curable resin composition is injected directly into fiber preform, and then the resin-infused preform is cured. When the curable resin composition of the present disclosure is used in resin infusion methods, it is preferred that a catalyst, e.g. the phenol compound disclosed herein, is included.
- Eight different resin blends were prepared according to the formulations shown in Table 1. All values are in weight percentage unless stated otherwise.
TABLE 1 Reagents RD2011-029 Bis-BOX m-Bis-BOX Araldite® CY-179 Pa-Type BOX Tris BOX m-Tris-BOX p-Tris-BOX TDP Formulation 1 68 23 9 Formulation 4 70 30 Formulation 5 48.11 23.25 19.55 9.1 Formulation 6 47.52 22.96 20.54 8.98 Formulation 9 35 30 35 Formulation 10 48 23 20 9 Formulation 11 0 23 68 9 Formulation 12 58 23 10 9 - RD2011-29 (Bisphenol A benzoxazine) and Araldite CY179 (cycloaliphatic epoxy) were supplied by Huntsman Advanced Materials. TDP refers to thiodiphenol.
-
-
- 150 g (0.49 mol) of 1,1,1-tris(4-hydroxyphenyl)ethane and 93 g (3.1 mol) paraformaldehyde were thoroughly mixed in a 2L glass reactor equipped with a mechanical stirrer at room temperature. Then 143.6 g (1.54 mol) of aniline was added at room temperature to avoid foaming. The reaction mixture was stirred with the slow addition of aniline at room temperature. After the internal reaction temperature cools to 60°C, the reactor was then submerged in an oil-bath preheated at 80°C. The resulting reaction mixture was a viscous semi-solid. The oil bath was heated to 110°C for 30 minutes. The oil bath was then heated to 130°C, when the internal temperature was above 110°C the reaction timer was set for 30 minutes. After 30 minutes, the molten reaction mixture was poured into an aluminum dish using a spatula to distribute the resin evenly over the pan and allowed to cool to room temperature. The resulting gold crystalline product was then ground into a powder. The powder was washed twice in 2L of a 1N NaOH solution at 70°C and in 2L of water at the same temperature as many times as needed to obtain a neutral pH. The product was dried in a vacuum oven for a week at 45°C.
- "p-Tris-BOX" refers to the p-tris benzoxazine compound (2) discussed above and was synthesized according to the method disclosed in
, filed on 12/08/2014 and assigned to Cytec Industries Inc.U.S. Patent Application No. 14/562,799 - Resin films were formed from the resin formulations disclosed on Table 1. Each resin film had a film weight of -39 gsm. Prepregs were made by impregnating unidirectional IM7 carbon fibers in web form with the resin films using a hot-melt lamination method. The target fabric areal weight (FAW) for the carbon fibers was 145 gsm and 35% resin content per prepreg. With the use of hot- melt prepregging equipment, two resin films were applied to a unidirectional carbon fiber web on both the top and bottom simultaneously, and impregnation was done with the aid of a hot plate heated to temperature between 160°F and 230°F. Composite laminate was made by laying up 24 prepreg plies according to orientation [+45/90/-45/0]3s to create a composite panel. During composite panel fabrication, debulking was also carried out every 4th ply, for 3 minutes under vacuum. Subsequently, the composite panel was vacuum bagged and cured in an autoclave at 8.16 bars for 2h at 180°C and then an additional 2h at 200°C.
- The cured composite panels were tested to determine open hole compression (OHC) and open hole tension (OHT) performance using ASTM test methods D6484 and D766 respectively.
- To obtain data for OHC, 30,48cm x 3.81 cm, 12 x 1.5 inch test specimens of cured composite panels were made. A 0.635cm, 0.25 inch hole was drilled in the center of each test specimen. Specimens were conditioned by immersing specimens in a water bath set at 71 °C for 2 weeks.
- The OHC results are shown in Table 2.
TABLE 2 Open Hole Compression (OHC) Test Values (MPa) Dry (23°C) Wet* (82°C) Wet* (121 °C) Wet* (149°C) Formulation 1 (not according to the invention) 349.6 322 301.3 240.6 Formulation 4 (not according to the invention) 357.2 342.7 251.7 128.9 Formulation 5 368.2 328.9 306.1 269.6 Formulation 6 (not according to the invention) 340.6 321.3 310.3 264.1 Formulation 9 348.2 318.5 290.3 190.3 Formulation 10 363.4 340 325 289.7 Formulation 11 355.8 340 313 289.6 Formulation 12 367 329 311.7 293 *conditioned: 2-week water soak - The resin formulations that contained both the Araldite CY-179 cycloaliphatic epoxy and tri-functional benzoxazines (Formulations 5, 10-12) yielded the best wet OHC performance at higher temperatures, 121°C and 149°C. These high values in wet OHC at 121°C and 149°C were also accompanied by an increase in dry and wet Tg as compared to other resin formulations, see Table 3.
TABLE 3 Composite Tg (°C) as determined by DMTA Resin Formulation 1 (not according to the invention) 4 (not according to the invention) 5 6 (not according to the invention) 9 10 11 12 Dry Tg (E') onset 208.5 168.7 228.7 231.1 181.4 229 235 251 Wet Tg (E') onset 169.9 148.6 181.1 180.8 150.1 182 183 189 - Tg was measured by Dynamic Mechanical Thermal Analysis (DMTA). It was observed that the tri-functional benzoxazines lowered the Tg of the benzoxazine composites that contained no cycloaliphatic epoxy (Formulation 9). Again, the increase in Tg was achieved with having both the cycloaliphatic epoxy and tri-functional benzoxazines in the resin system.
- The open hole tension (OHT) values for composite panels based on Formulations 1, 4, 5, 6, and 9 were measured and are reported in Table 4.
TABLE 4 Open Hole Tension (OHT) Test Values (MPa) Condition Resin 23°C -59°C Formulation 1 (not according to the invention) 483.3 473.7 Formulation 4 (not according to the invention) 628.1 628.1 Formulation 5 549.5 530.2 Formulation 6 (not according to the invention) 582.6 557.1 Formulation 9 612.3 625.4 - Composite panels based on Formulations 5, 9 had tension values greater than the composite panel based on Formulation 1. More importantly, the combination of tri-functional benzoxazine and epoxy (Formulation 5) did not cause a decrease in the OHT strength, instead an increase was obtained. This is unexpected because an increase in compressive strength is typically accompanied by a loss in tensile strength. This was not the case with the use of Formulation 5.
Claims (11)
- The curable resin composition of claim 1 further comprising:
(C) a phenol compound as a catalyst. - The curable resin composition of claim 1 or 2 further comprising:
(D) a di-functional benzoxazine compound. - The curable resin composition of claim 3, wherein the benzoxazine compounds (B) and (D) constitute for more than 50% by weight based on the total weight of the composition.
- The curable resin composition according to any one of claims 3 to 5, wherein the di-functional benzoxazine compound (D) is represented by the following structure:
where:Z1 is selected from a direct bond, -C(R3)(R4)-, -C(R3)(aryl)-, -C(O)-, -S-, -O-, -S(O)-, -S(O)2-, a divalent heterocycle and -[C(R3)(R4)]x-arylene-[C(R5)(R6)]y-, or the two benzyl rings of the benzoxazine moieties may be fused; andR1 and R2 are independently selected from alkyl, cycloalkyl, and aryl, wherein the cycloalkyl and aryl groups are optionally substituted by a substituent selected from: C1-8 alkyl, halogen and amine groups, and where substituted, one or more substituent groups may be present on each cycloalkyl and aryl group;R3, R4, R5 and R6 are independently selected from H, C1-8 alkyl, and halogenated alkyl; andx and y are independently 0 or 1. - The curable resin composition according to any one of claims 2 to 6, wherein the phenol compound (C) is thiodiphenol (TDP).
- A composite material comprising reinforcement fibers impregnated or infused with the curable composition according to any one of claims 1 to 7.
- The composite material of claim 8, wherein the reinforcement fibers are selected from carbon fibers, glass fibers, and aramid fibers.
- A prepreg comprising reinforcement fibers impregnated or infused with the curable composition according to any one of claims 1 to 7, wherein reinforcement fibers are in the form of unidirectional fibers or a fabric.
- A cured composite part produced from a method comprising: (i) impregnating or infusing reinforcement fibers with the curable composition according to any one of claims 1 to 10; and (ii) curing the resin-impregnated or resin-infused fibers.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562174759P | 2015-06-12 | 2015-06-12 | |
| PCT/US2016/034269 WO2016200617A1 (en) | 2015-06-12 | 2016-05-26 | Curable compositions containing benzoxazine epoxy blend and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3307805A1 EP3307805A1 (en) | 2018-04-18 |
| EP3307805B1 true EP3307805B1 (en) | 2021-07-07 |
Family
ID=56119775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP16728796.0A Active EP3307805B1 (en) | 2015-06-12 | 2016-05-26 | Curable compositions containing benzoxazine epoxy blend and use thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10221313B2 (en) |
| EP (1) | EP3307805B1 (en) |
| JP (1) | JP7041518B2 (en) |
| KR (1) | KR102478108B1 (en) |
| CN (1) | CN107743508B (en) |
| AU (1) | AU2016274314B2 (en) |
| BR (1) | BR112017026532B1 (en) |
| CA (1) | CA2987755A1 (en) |
| RU (1) | RU2749037C2 (en) |
| TW (1) | TWI705064B (en) |
| WO (1) | WO2016200617A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106700548B (en) * | 2016-12-30 | 2019-04-30 | 广东生益科技股份有限公司 | A kind of preparation method containing benzoxazine resin composition and the prepreg and laminate being made from it |
| CN106995582A (en) * | 2017-05-16 | 2017-08-01 | 江苏恒神股份有限公司 | A kind of curable resin composition and its application containing benzoxazine and epoxy resin blend |
| CN107216608B (en) * | 2017-06-01 | 2019-08-20 | 杭州中一科技有限公司 | A kind of compositions of thermosetting resin of highly corrosion resistant and its application |
| CN107353594A (en) * | 2017-07-24 | 2017-11-17 | 无锡南理工科技发展有限公司 | A kind of curable resin blend composition and its application |
| TWI656172B (en) * | 2017-09-18 | 2019-04-11 | 台燿科技股份有限公司 | Solvent-free resin composition and uses of the same |
| CN110713691B (en) * | 2019-09-19 | 2022-10-21 | 航天科工(长沙)新材料研究院有限公司 | Benzoxazine and preparation method thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4245377B2 (en) | 2003-03-07 | 2009-03-25 | 株式会社Adeka | High elastic epoxy resin composition |
| TWI295288B (en) | 2006-08-17 | 2008-04-01 | Univ Nat Chunghsing | New route for the synthesis of benzoxazine |
| ES2621154T3 (en) * | 2006-11-13 | 2017-07-03 | Henkel IP & Holding GmbH | Benzoxazine compositions with core-wrap rubbers |
| WO2009137144A2 (en) * | 2008-02-21 | 2009-11-12 | Huntsman Advanced Materials Americas Inc. | Halogen-free benzoxazine based curable compositions for high tg applications |
| CN102373621B (en) * | 2010-08-20 | 2014-01-22 | 南亚塑胶工业股份有限公司 | High glass transition temperature resin varnish composition applied to glass fiber laminates |
| CN103415661A (en) | 2011-03-16 | 2013-11-27 | 英威达技术有限公司 | Processes to make water and oil repellent bcf yarn |
| GB201205574D0 (en) * | 2012-03-29 | 2012-05-16 | Cytec Tech Corp | Benzoxazines and compositions containing the same |
| GB201322758D0 (en) | 2013-12-20 | 2014-02-05 | Cytec Ind Inc | Multifunctional benzoxazines and composite materials incorporating then same |
| JP6550136B2 (en) * | 2014-12-29 | 2019-07-24 | サイテック インダストリーズ インコーポレイテッド | Trifunctional benzoxazines and their use in curable resin compositions and composites |
-
2016
- 2016-05-26 RU RU2018100630A patent/RU2749037C2/en active
- 2016-05-26 EP EP16728796.0A patent/EP3307805B1/en active Active
- 2016-05-26 JP JP2017564496A patent/JP7041518B2/en active Active
- 2016-05-26 WO PCT/US2016/034269 patent/WO2016200617A1/en not_active Ceased
- 2016-05-26 CA CA2987755A patent/CA2987755A1/en active Pending
- 2016-05-26 KR KR1020177036527A patent/KR102478108B1/en active Active
- 2016-05-26 CN CN201680034414.3A patent/CN107743508B/en active Active
- 2016-05-26 AU AU2016274314A patent/AU2016274314B2/en not_active Ceased
- 2016-05-26 BR BR112017026532-0A patent/BR112017026532B1/en not_active IP Right Cessation
- 2016-06-08 US US15/176,226 patent/US10221313B2/en active Active
- 2016-06-08 TW TW105118199A patent/TWI705064B/en not_active IP Right Cessation
Non-Patent Citations (1)
| Title |
|---|
| None * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107743508B (en) | 2020-07-03 |
| AU2016274314A1 (en) | 2017-12-14 |
| WO2016200617A1 (en) | 2016-12-15 |
| KR20180022676A (en) | 2018-03-06 |
| EP3307805A1 (en) | 2018-04-18 |
| US10221313B2 (en) | 2019-03-05 |
| AU2016274314B2 (en) | 2020-05-21 |
| US20160362554A1 (en) | 2016-12-15 |
| TWI705064B (en) | 2020-09-21 |
| BR112017026532A2 (en) | 2018-08-14 |
| RU2749037C2 (en) | 2021-06-03 |
| CA2987755A1 (en) | 2016-12-15 |
| JP7041518B2 (en) | 2022-03-24 |
| RU2018100630A (en) | 2019-07-12 |
| BR112017026532B1 (en) | 2021-11-16 |
| KR102478108B1 (en) | 2022-12-15 |
| TW201706269A (en) | 2017-02-16 |
| JP2018524433A (en) | 2018-08-30 |
| CN107743508A (en) | 2018-02-27 |
| RU2018100630A3 (en) | 2019-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3307805B1 (en) | Curable compositions containing benzoxazine epoxy blend and use thereof | |
| EP2831052B1 (en) | Benzoxazines and compositions containing the same | |
| US20230133556A1 (en) | Benzoxazines and compositions containing the same | |
| EP3240780B1 (en) | Trifunctional benzoxazine and use thereof in curable resin compositions and composite materials | |
| EP3233960B1 (en) | Epoxy-based resin composition for composite materials |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20180112 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20200428 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20200911 |
|
| GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| INTC | Intention to grant announced (deleted) | ||
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20210303 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: DYERS, LEON Inventor name: BONNEAU, MARK RICHARD Inventor name: GRIFFIN, JAMES MARTIN |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1408569 Country of ref document: AT Kind code of ref document: T Effective date: 20210715 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602016060303 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20210707 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1408569 Country of ref document: AT Kind code of ref document: T Effective date: 20210707 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211108 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211007 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211007 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211008 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602016060303 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 |
|
| 26N | No opposition filed |
Effective date: 20220408 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20220531 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220526 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220531 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220531 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220526 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220531 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230624 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20160526 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20250402 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20250401 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20250422 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20250401 Year of fee payment: 10 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210707 |